NeuroCog Trials Names Leading Industry Professional To Head Business Development

Jul 20, 2015, 12:26 ET from NeuroCog Trials

DURHAM, N.C., July 20, 2015 /PRNewswire/ -- NeuroCog Trials announced the appointment of Brian K. Saxby, PhD, to the new position of Vice President, Business Development. Dr. Saxby will focus on expanding NeuroCog Trials' industry leading offerings into new therapeutic areas and disease states as well as introducing the Company's newest services and validated assessments to the market.

"While some pharmaceutical companies have been reducing their investment in CNS, we have been able to have substantial growth over the past few years," said Richard Keefe, PhD, Founder and Chief Executive Officer of NeuroCog Trials. "We have had great success in areas that were once new to us such as Alzheimer's disease, healthy aging, and non-CNS diseases, and we are now in a very fortunate position of being able to apply our innovative methods beyond our core areas of work.  We feel that Dr. Saxby's vast knowledge of new drug development and assessment methods will enable us to move into new areas of opportunity to apply our expertise. We expect tremendous gains in our capacity to provide key services for increasingly larger trials across a broad range of CNS and other therapeutic areas."

Dr. Saxby has more than 15 years of clinical trials' experience and began his career in the UK at an academic site conducting his doctoral research in hypertension and cognitive decline in the elderly.  In 2004, he took on a scientific position for a computerized cognitive test provider and became Head of Science in 2008.  During his scientific tenure, Dr. Saxby was able to foster key relationships with decision-makers.  In 2009, after relocating to the US, his solid reputation allowed him to transition into business development, with notable success spearheading Cambridge Cognition's product development to address the Human Abuse Liability trials market.  Most recently, Dr. Saxby has been involved in Rater Training and in-study surveillance methods for ensuring quality of Clinician-Reported Outcomes (ClinROs), as Senior Director at ProPhase.

Dr. Saxby earned his B.Sc. and Ph.D. in Psychology from Newcastle University (UK) and is a Visiting Researcher at the Institute for Ageing.  He has over 30 publications involving cognitive assessment in a number of therapeutic areas including dementia, depression, hypertension and cardiology.

About NeuroCog Trials

NeuroCog Trials Inc. is the leading cognition services company for the pharmaceutical industry.  For more than 10 years, NeuroCog Trials has provided  consulting, site screening, rater training and certification, and data review services to more than 85 clinical trials in over 25 countries.  NeuroCog Trials has certified more than 6,000 neurocognitive testers and assured data quality for over 100,000 assessments across a variety of therapeutic areas, including schizophrenia, Alzheimer's disease, major depressive disorder, bipolar disorder and brain cancer.  Our mission is to facilitate the development of novel therapies to enhance cognition.  We bring to all of our work deep expertise, strategic innovation, and an unwavering commitment to research excellence.

For more information on NeuroCog Trials, its services, and licensing inquiries for its exclusive neuropsychological and functional capacity assessment batteries, please see www.neurocogtrials.com.

Contact

Nicole M. Turcotte

Telephone

+1 919-401-4642

Email

nicole.turcotte@neurocogtrials.com

Website

www.neurocogtrials.com

Logo - http://photos.prnewswire.com/prnh/20150720/238213LOGO

SOURCE NeuroCog Trials



RELATED LINKS

http://www.neurocogtrials.com